ASCO 2016

Bayer at 2016 ASCO Annual Meeting

At this year’s ASCO congress, Bayer showcased the latest research for its oncology portfolio, including potential new uses for its approved therapies in other tumor types, as well as research on investigational compounds for hard-to-treat cancers like advanced prostate cancer and mesothelioma.

At Bayer, we are encouraged about the future of cancer treatments. As we solidify new leadership, expand the breadth of our existing portfolio and continue to explore new tumor types and a growing pipeline, we stand ready to play our part in the fight against cancer – all with the support and collaboration of our many partners. Our presence at ASCO underscores our commitment to finding treatments for patients who need them most.

Hearing from Our Executives:

Robert LaCaze, Head of the Therapeutic Area Oncology
Robert LaCaze, Head of the Therapeutic Area Oncology

“This is my first ASCO with Bayer, after more than 15 years in the oncology industry. I am struck by the investment the company is making in its oncology portfolio, tripling its size in nearly three years and developing several promising platform candidates that show solid potential. In the past five years, Bayer has transformed from a company with one cancer therapy in two indications, to one with three approved cancer treatments in six indications.”

- Robert LaCaze, Head of the Therapeutic Area Oncology

Habib Dable, President, U.S. Pharmaceuticals
Habib Dable, President, U.S. Pharmaceuticals

“At Bayer, being viewed as a partner of choice is a critical success pillar for our company. It’s when we work as partners with our broad network of patient advocacy groups that we truly glean insights and can ensure the patient community benefits from the collective wisdom of many who are on the front lines of patient care. With that collaborative spirit in mind, we see an opportunity to evolve our long-standing relationships with the advocacy community by bringing them together at ASCO.”

- Habib Dable, President, U.S. Pharmaceuticals

Shannon Campbell, U.S. Commercial
Shannon Campbell, U.S. Commercial

“The brightest minds come together at ASCO to share knowledge. We undertake research that is vital to advancing care, and look to other areas such as patient behavior to uncover insights that can be just as impactful. As part of our commitment to patients, we see value in changing the conversation they are having with their doctors. Through awareness programs, we can help men better understand the impact of progressing disease and enable them to recognize signs and become more vocal when their symptoms start to change.”

- Shannon Campbell, U.S. Commercial

Volker Wagner, Clinical Development
Volker Wagner, Clinical Development

“Radium was first discovered more than a century ago, but only recently has science effectively utilized isotopes to evolve the element into a modern anticancer therapy that has a demonstrated survival benefit for men with metastatic castration-resistant prostate cancer. Bayer has been a pioneer in this area and ASCO presents another opportunity to share data that support this leadership as we continue to explore treatment approaches that can offer meaningful progress to doctors and patients battling the toughest cancers.”

- Volker Wagner, Clinical Development

Andreas Busch, Head of Drug Discovery
Andreas Busch, Head of Drug Discovery

“Our oncology research prioritizes treatments that show promise for combating hard-to-treat cancers, and over the past three years we have tripled our oncology pipeline, with 21 projects currently in clinical development. For me, ASCO’s theme of collective wisdom is rooted in complementing our own capabilities through alliances with industry and academic partners to translate our combined scientific know-how and research expertise into impactful solutions and medicines for patients.”

- Andreas Busch, Head of Drug Discovery

Mark Rutstein SVP, Oncology BU
Mark Rutstein SVP, Oncology BU

“Bayer has a legacy of successfully exploring the use of kinase inhibitors across a wide range of difficult-to-treat cancers so that we can extend the use of these therapies to every patient that may derive benefit. Our most recent venture involves a late-stage clinical study in hepatocellular carcinoma, where for the first time a tyrosine kinase inhibitor demonstrated a survival benefit in the second line setting. This is a prime example of how we at Bayer continue to investigate the full clinical utility of all our cancer treatments.”

- Mark Rutstein SVP, Oncology BU